Structure-based lead identification of ATP-competitive MK2 inhibitors.
Barf T., Kaptein A., de Wilde S., van der Heijden R., van Someren R., Demont D., Schultz-Fademrecht C., Versteegh J., van Zeeland M., Seegers N., Kazemier B., van de Kar B., van Hoek M., de Roos J., Klop H., Smeets R., Hofstra C., Hornberg J., Oubrie A.
MK2 kinase is a promising drug discovery target for the treatment of inflammatory diseases. Here, we describe the discovery of novel MK2 inhibitors using X-ray crystallography and structure-based drug design. The lead has in vivo efficacy in a short-term preclinical model.
Bioorg. Med. Chem. Lett. 21:3818-3822(2011) [PubMed] [Europe PMC]